Navigation Links
Drug Inhibits Colon Cancer in Mice
Date:2/12/2009

Treated with enzastaurin, even tumors that did develop weren't as advanced, study finds

THURSDAY, Feb. 12 (HealthDay News) -- A drug called enzastaurin significantly reduced the development of colon cancer in mice, and tumors that did develop were less advanced and aggressive than those in mice that didn't receive the drug, according to a study by researchers at the Mayo Clinic in Florida.

The findings, coupled with the fact that the drug appears to have minimal side effects, suggest that enzastaurin might offer an effective chemopreventive treatment in people at high risk for colon cancer, the researchers said. The study is to be published in the Feb. 15 issue of the journal Cancer Research.

"There is a need for an agent that has a proven ability to reduce colon cancer risk, and this study suggests that enzastaurin could be uniquely effective," senior investigator Nicole Murray, of the department of cancer biology, said in a Mayo news release.

Enzastaurin is designed to suppress signaling through the PKC-beta pathway. In a previous study, the Mayo team found that the pathway is necessary for the start of colon cancer in mice exposed to a carcinogen.

"These mice develop tumors similar to tumors found in humans, but mice without the PKC-beta gene do not," Murray said.

In the new study, the Mayo researchers gave enzastaurin daily to one group of mice and then exposed them, as well as a control group of mice that didn't receive the drug, to a carcinogen that causes colon tumors.

After 22 weeks, 50 percent of the treated mice and 80 percent of the untreated mice had developed tumors. The tumors that did develop in the treated mice were not as advanced as those in the untreated mice.

Enzastaurin is currently being tested to treat a range of human cancers, including B-cell lymphoma and high-grade brain gliomas.

More information

The U.S. National Cancer Institute has more about colon cancer prevention.



-- Robert Preidt



SOURCE: Mayo Clinic, news release, Feb. 11, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Oncogene inhibits tumor suppressor to promote cancer: Study links B-RAF and LKB1
2. Herpes drug inhibits HIV replication, but with a price
3. Grapefruit Compound Inhibits Hepatitis C Virus
4. Calorie restriction inhibits, obesity fuels development of epithelial cancers
5. Calorie restriction limits Calorie restriction inhibits, obesity fuels development of epithelial can
6. Ingredient found in green tea significantly inhibits breast cancer growth in female mice
7. Penn scientists find a protein that inhibits Ebola from reaching out to infect neighboring cells
8. Embryonic Stem Cell Protein Inhibits Melanoma
9. Blocking protein kills prostate cancer cells, inhibits tumor growth, Jefferson scientists find
10. Helicobacter pylori inhibits intercellular communication of cultured gastric cells
11. Rural Areas Able to Increase Colon Cancer Screenings
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Inhibits Colon Cancer in Mice
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced two ... support the company’s continued investment and strategic growth plans in the Asia Pacific ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... supply chain solutions, today announced the organization has earned its ISO 13485 certification, ... and is compliant with all rules and policies associated with ISO quality standard ...
(Date:5/26/2016)... New York, NY (PRWEB) , ... May 26, ... ... cell researcher, founder of Mehling Orthopedics and chief medical officer of Blue Horizon ... Musculoskeletal Disease and Regeneration. The conference was held during May 5-6, 2016 in ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... to oncology professionals, has added National Cancer Institute-designated University of Virginia (UVA) ... In this new partnership, OncLive’s editorial and marketing teams will publicize and promote ...
(Date:5/26/2016)... ... May 26, 2016 , ... Metcalf & ... over 20 years of experience in leading technology and human resources operations for ... university teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica radio show , ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 25,2016 FDA 510(k) clearance ... platform for urological and surgical applications ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) ... the US with the 12 th 510(k) ... (FDA). This new FDA clearance covers Confocal Miniprobes ...
(Date:5/25/2016)... , May 25, 2016  According to Kalorama ... $381 billion in 2015.  Though these are challenging ... of opportunity for success for companies that remain ... search of new growth prospects medical device companies ... research and development (R&D) than do companies in ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
Breaking Medicine Technology: